drugset / Trial / NCT07643636
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
NaSingle-groupOpen-labelTreatment
Summary
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation mechanism.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Homoharringtonine | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |
| Subject | Venetoclax | Small molecule | — | — |